Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 12,556 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: combined therapy treatment Clear all

Conditions: Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions: Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: DCVAC/PCa, Placebo; Biological
Lead sponsor: SOTIO a.s.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 58
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more

Conditions: Prostate Cancer
Interventions: bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT); Drug · Procedure
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma
Interventions: Bendamustine, Pentostatin, Ofatumumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
Interventions: Denosumab, Pembrolizumab, Nivolumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Manchester, New Hampshire • Chapel Hill, North Carolina

Conditions: Stroke, Cerebrovascular Accident, CVA, Acute Stroke, Acute Cerebrovascular Accident, Apoplexy
Interventions: Real Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more

Conditions: Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, Leucovorin, NIS793, Chemoradiation, Surgery; Drug · Radiation · Procedure
Lead sponsor: Kimberly Perez, MD; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Treatment Resistant
Interventions: dextromethorphan/quinidine; Drug
Lead sponsor: James Murrough; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Infertility
Interventions: Bravelle, Menopur; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Lone Tree, Colorado • Clearwater, Florida • Atlanta, Georgia + 7 more

Conditions: Hypertension
Interventions: EHMI, Nurse Educator + EHMI; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 8
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: bevacizumab, erlotinib HCl, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 4
States / cities: Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more

Conditions: Substance Use Disorders
Interventions: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), Relaxation Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Wilkinsburg, Pennsylvania

Conditions: Post-traumatic Stress Disorder, Stress Disorders, Anxiety, Depression
Interventions: Cognitive Processing Therapy, Waitlist Placebo; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glioblastoma (GBM)
Interventions: DOC1021, Tumor resection, Temodar (Temozolomide), SOC cranial radiation; Biological · Procedure · Drug + 1 more
Lead sponsor: Diakonos Oncology Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • Newport Beach, California + 14 more

Conditions: Metastatic Breast Cancer
Interventions: Lasofoxifene and abemaciclib (VERZENIO (R)).; Drug
Lead sponsor: Sermonix Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Yuma, Arizona • Fountain Valley, California + 12 more

Conditions: Polycystic Ovary Syndrome
Interventions: Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Plasma Cell Myeloma Refractory
Interventions: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Alcohol Drinking, Opioid Use
Interventions: Alcohol-targeted Brief Intervention-Medication Therapy Management, Standard medication counseling; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes, Muscular Atrophy, Sedentary Behavior, Exercise, Pre-diabetes
Interventions: Bed Rest Intervention, Exercise Program; Behavioral
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 60 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Depression, Psychosis, Anhedonia
Interventions: Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions: On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist; Drug
Lead sponsor: Ruth M. Rothstein CORE Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Non-invasive Brain Stimulation and Occupational Therapy To Enhance Stroke Recovery

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Nuedexta in Treatment-Resistant Major Depression

Menopur Mixed Protocol

Northwestern University and Access Community Health Network Medication Education Study

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Distress Tolerance for Benzodiazepine Discontinuation

Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

Vaccine Therapy in Treating Patients With Melanoma

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Co-Use of Opioid Medications and Alcohol Prevention Study

Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration